MMP2 and prostate carcinoma: Additionally, CTD inhibited the expression of matrix metalloproteinases 2 and 9 (MMP2/9), interfered with the transamidation of Exo70, modulated PP2A levels, regulated autophagy, induce apoptosis and repair DNA repair for the treatment of melanoma [61], cervical cancer [62], pancreatic cancer [63], glioblastoma [64], prostate cancer [65], lung cancer [66], skin cancer [67], cholangiocarcinoma [68] and promyelocytic leukemia [69].